Last reviewed · How we verify
Period 2 - Treatment Sequence AB
At a glance
| Generic name | Period 2 - Treatment Sequence AB |
|---|---|
| Also known as | ribaxamase |
| Sponsor | Theriva Biologics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants (PHASE1)
- Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (PHASE2)
- A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants (PHASE1)
- A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants (PHASE1)
- Personalized Music Therapy for Preterm Infants (NA)
- Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants (PHASE1)
- Increasing Engagement and Positive Emotional Behavior of Older Adults With Mild-Moderate Dementia With the Use of Motion-Based Technology and Meaningful Activities (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Period 2 - Treatment Sequence AB CI brief — competitive landscape report
- Period 2 - Treatment Sequence AB updates RSS · CI watch RSS
- Theriva Biologics, Inc. portfolio CI